Compare RMT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RMT | ANL |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.0M | 731.6M |
| IPO Year | N/A | 2022 |
| Metric | RMT | ANL |
|---|---|---|
| Price | $13.81 | $12.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 99.6K | ★ 289.2K |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.66 | $0.88 |
| 52 Week High | $13.97 | $17.25 |
| Indicator | RMT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 65.61 | 46.26 |
| Support Level | $10.32 | $11.86 |
| Resistance Level | $13.97 | $12.09 |
| Average True Range (ATR) | 0.27 | 1.33 |
| MACD | -0.04 | -0.37 |
| Stochastic Oscillator | 88.08 | 31.46 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.